Anzeige
Mehr »
Mittwoch, 03.06.2026 - Börsentäglich über 12.000 News
UraniumX blickt nach frühem Bohr-Erfolg in eine goldene Zukunft der Atomkraft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853081 | ISIN: US0010551028 | Ticker-Symbol: AFL
Tradegate
03.06.26 | 16:23
99,20 Euro
+1,56 % +1,52
1-Jahres-Chart
AFLAC INC Chart 1 Jahr
5-Tage-Chart
AFLAC INC 5-Tage-Chart
RealtimeGeldBriefZeit
100,05100,2519:38
100,05100,2019:38
ACCESS Newswire
148 Leser
Artikel bewerten:
(0)

Aflac Incorporated: Check for Cancer Champion Dr. Heather Bittner Fagan Brings Cancer Prevention to the Frontlines of Care

NORTHAMPTON, MA / ACCESS Newswire / June 3, 2026 / Originally published on Aflac Newsroom

For more than 20 years, Dr. Heather Bittner Fagan has been practicing and teaching family medicine in Claymont, Delaware, a medically underserved area where disparities in cancer outcomes mirror those in communities across the country. But her influence extends far beyond a single exam room. Through nationally recognized research and leadership at the intersection of primary care and cancer prevention, Dr. Fagan has helped shape how regular cancer screening reaches patients who have may have otherwise been left behind.

A family physician grounded in cancer prevention

A practicing family physician, Dr. Fagan has built her career on a simple but powerful idea: Primary care doctors are important, trusted messengers within vulnerable populations.

"The data and our experience tell us that patients really listen to their primary care doctors - they trust us," Dr. Fagan said. "Cancer prevention is a team sport. We need to work together, within and outside of patient visits and across specialties, to do everything we can to help all of our patients access evidence-based screening. Working together, we can create more birthdays."

That philosophy has guided a national body of research examining how evidence-based screening guidelines can be translated into real-world primary care practice. Dr. Fagan has published extensively in leading peer-reviewed journals with studies that look at simple, practical ways primary care doctors can help more patients get screened for cancer, such as guiding patients through the process, having clearer conversations about screening and making it easier to fit screenings into routine care.

It is because of her work to help improve cancer screening rates across the country that Dr. Fagan has been honored as an Aflac Check for Cancer Champion.

Influencing care guidelines within the community and across the country

Colleagues describe Dr. Fagan as a bridge-builder - someone fluent in both the language of frontline care and national policy. She is firmly rooted in her community-based practice in Claymont, but her reach extends far beyond that.

One of Dr. Fagan's most influential areas of research has been around lung cancer screening, a lifesaving tool that remains underused nationwide with national screening rates remaining low - only about 1 in 5 eligible individuals (18.7%) in the U.S. are up to date with this important screening, according to the American Cancer Society. Dr. Fagan's work has tackled that gap head on, studying practical strategies like helping patients make decisions over the phone and finding ways for primary care teams to lead outreach efforts.

Her expertise led to her selection as a consultant to the American Cancer Society, where she provides input on the organization's lung cancer screening guidelines. In that role, she helped ensure that evolving recommendations were not only scientifically rigorous but also feasible in everyday primary care settings, particularly those serving vulnerable populations. Dr. Fagan has also served as an invited member of the National Lung Cancer Roundtable, further amplifying the voice of primary care in national cancer prevention conversations.

It is her dual role - as clinician and researcher - that has made her work both credible and impactful. And in recognition of this leadership, Dr. Fagan has received numerous honors, including the American Cancer Society's Cancer Control Career Development Award, a distinction reserved for emerging national leaders in cancer prevention and control.

As cancer prevention continues to evolve, Dr. Fagan remains focused on the same throughline that has defined her career: equity. By looking at the daily realities of primary care, she has helped ensure that advances in cancer screening and early detection are not limited to those with the fewest barriers, but extended to communities that are in great need. And that makes her a true Aflac Check for Cancer Champion.

The Check for Cancer Champions program is part of Aflac's Check for Cancer initiative, a bold, national movement to increase cancer screenings by 10% over 10 years. Learn more about the Check for Cancer movement by visiting Aflac.com/CheckForCancer.


Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999??

Z2600335 EXP 5/27

Find more stories and multimedia from Aflac Incorporated at 3blmedia.com.

Contact Info:
Spokesperson: Aflac Incorporated
Website: https://www.3blmedia.com/profiles/aflac-incorporated
Email: info@3blmedia.com

SOURCE: Aflac Incorporated



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/banking-and-financial-services/check-for-cancer-champion-dr.-heather-bittner-fagan-brings-cancer-pr-1173013

© 2026 ACCESS Newswire
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.